X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy’s Vs Ranbaxy Vs Teva - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 27, 2003

    Dr. Reddy’s Vs Ranbaxy Vs Teva

    ‘Generics’ has been the buzzword among Indian pharma majors for some time now, and not without reason. There exists significant potential for generics manufacturers in the regulated markets. Two Indian generics majors, Ranbaxy and Dr. Reddy’s (DRL), have been increasingly focusing on this market for sustained growth. But what would the future hold for companies that follow this business strategy? To get an understanding of the same we have compared two Indian generic companies with a global leader in the generic markets – Teva Pharmaceutical Industries Ltd.

    Teva is an Israeli pharmaceutical company specialising in the development, production and marketing of generics drugs. The company registered sales of US$ 2.5 bn in 2002, with North America and Europe contributing 89% of its revenues. Teva has also tasted success on the patented drugs front. The company is the developer and world wide exclusive rights holder for Copaxone, which is used for the treatment of multiple sclerosis. The drug notched revenues of US$ 539 m in 2002.

    Let us now briefly compare the three companies on various parameters.

    Financial comparison ($ m)
      Teva (Dec 02) Dr Reddy's (Mar 03) Ranbaxy (Dec 02)
    Net sales 2,519 380 764
    Sales growth (4 years CAGR) 25.2 53.7 22.8
    Operating Profit 600 91 170
    OPM (%) 23.8 28.3 22.2
    PAT 410 74 125
    PAT growth (4 years CAGR) 52.0 80.3 46.9
    NPM (%) 16.3 19.5 16.4
    R&D as % of revenue 7.7 7.6 5.6

    Teva is way ahead of its Indian counterparts in respect of revenues and profits. This is mainly on account of the sale of patented drug Copaxone and due to higher number of ANDA approvals. However, despite the above, in terms of efficiency and growth, there is little difference between the three companies. While DRL leads the pack in terms of operational and net profit margins, the difference between Ranbaxy and Teva is negligible.

    With respect to R&D spendings as a percentage of sales, DRL is at par with Teva, while Ranbaxy lags behind. However, Teva receives grants from the Israel government and third party research participants for R&D spendings. If these are excluded, R&D as a percentage of revenues will drop to 6.6% from 7.7%. This indicates that the Indian companies are in the right direction.

    Geographical revenue distribution (%)
      Teva (Jan 03-Mar 03) Dr. Reddy's (FY03) Ranbaxy (FY03)
    USA 64 32 38
    Europe 25 8 7
    ROW 11 60 55

    Moving away from the financials of the three companies, let us now examine the quality of business done by them. US generics market is key to the growth for all three companies. However, while Teva has 64% of its revenues coming from USA, DRL and Ranbaxy have only 32% and 38% respectively of their revenues from USA. This is primarily due to a larger generics portfolio of Teva as compared to DRL and Ranbaxy. Teva has had more successes as far as Para IV ANDA filings are concerned. In 2002, Teva made 39 Para IV ANDA filings as against 10 and 7 by DRL and Ranbaxy respectively.

    ANDA filings in 2002
      Approved Pending approval
    Teva 48 11
    Dr. Reddy's 11 3
    Ranbaxy 11 23

    In terms of overall ANDA (all 4 paras) filings and approvals in the US, Teva is again way ahead of its Indian counterparts. In 2002, where Teva made 59 ANDA filings, DRL and Ranbaxy could manage only 14 and 34 filings respectively. However, DRL and Ranbaxy are increasingly focusing on raising the total number of ANDA filings and also improving the approvals to filings ratio.

    NCE Pipeline
      Research Pre Clinical Clinical Pre Filing Marketed
    Teva 2 1 6 1 1
    Dr. Reddy's 8 4 2 0 0
    Ranbaxy 4 2 3 0 0

    All the three companies have recognized the importance of New Chemical Entities (NCE) and new drug discovery. Teva has already developed and marketed its first patented drug Copaxone, which is used for the treatment of multiple sclerosis. Besides this, Teva has another drug Rasagiline for the treatment of Parkinson’s disease, which has completed the three phases of clinical trials and is being submitted for regulatory approval with the US authorities. DRL and Ranbaxy have started late in this field and hence most of their NCEs are in the early discovery stage or in the various clinical testing phases. However, a higher number of drugs in the initial research and pre-clinical stages indicate the two companies resolve for improving their position in new drug discovery research.

    Valuations
      Teva Dr. Reddy's Ranbaxy
    P/E 36.2 20.2 21.2
    ROE 22.4 31.5* 34.6
    ROA 8.9 27.5* 24.0
    * FY02 figures

    On the valuations front, we see that at current prices, DRL and Ranbaxy are getting a lower valuation as compared to Teva. This is probably due to the fact that the markets have factored Teva’s patented product Copaxone and larger generics portfolio into the price. Taking this into account and considering the similar business structure and the faster growth rates that the Indian companies are recording, there is good potential going forward for both DRL and Ranbaxy.

    Thus, while there is no comparison possible of DRL and Ranbaxy with Teva as far as size is concerned, in terms of efficiency and growth, the three companies are almost at par. DRL and Ranbaxy also have given a direction to their business. Although the two Indian companies are at a very nascent stage as compared with Teva, the size of the Israeli MNC is a good indicator of what DRL and Ranbaxy could achieve in the long term. Thus we reiterate what we have always been saying, 'Do not base your decision on the outcome of litigations'.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy’s Vs Ranbaxy Vs Teva". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB - IPCA LABS COMPARISON

    Compare Company With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS